Europe Bioanalytical Testing Services Market Forecast to 2030 - Regional Analysis - by Services (Pharmacokinetics, Biomarkers, Immunogenicity, Virology Testing, Cell-based assays, and Others); Disease Indication (Cardiovascular, Neurological Disorders, Me

Europe Bioanalytical Testing Services Market Forecast to 2030 - Regional Analysis - by Services (Pharmacokinetics, Biomarkers, Immunogenicity, Virology Testing, Cell-based assays, and Others); Disease Indication (Cardiovascular, Neurological Disorders, Metabolic Disorders, Autoimmune Disorders, Respiratory Diseases, Oncology, Sexual Health, Bone Disease, and Others); and End User [Pharmaceutical and Biopharmaceutical Companies, Contract Research Organization (CRO), Contract Development And Manufacturing Organization (CDMO), and Others]

The Europe bioanalytical testing services market was valued at US$ 1,374.48 million in 2022 and is expected to reach US$ 2,956.96 million by 2030; it is estimated to grow at a CAGR of 10.0% from 2022 to 2030.

High Demand for Analytical Testing of Biosimilars and Biologics Fuel the Europe Bioanalytical Testing Services Market

Biologics are among the most promising therapeutic areas important in the pharmaceutical market. The rising number of cases of chronic diseases such as inflammatory bowel diseases, cancer, and rheumatoid arthritis propels the demand for biologics. However, the high cost of biologics' has redirected the focus of drug developers and healthcare stakeholders toward biosimilars in recent years. Additionally, the imminent expiry of the patents and exclusivity periods of biologics have also created opportunities for the development of biosimilars. According to McKinsey & Co., ~19 high-volume biologics would lose exclusivity by 2025. Additionally, 39 more high-volume biologics are expected to lose patent protection between 2026 and 2032, with more biologics likely to follow. The Association for Accessible Medicines (AAM) expects a ~25% price drop on branded biologics on average after the launch of biosimilars because average biosimilar sales prices are ~50% lower than the original branded biologics.

The anticipated rise in biosimilar R&D would boost the demand for related bioanalytical testing services-compatibility studies for biosimilars, stability testing, product release testing, and biosimilar protein analysis-to reduce the risks involved with medication development. Thus, the rise in demand for analytical testing of biosimilars is boosting the growth of the bioanalytical testing services market.

Europe Bioanalytical Testing Services Market Overview

The bioanalytical testing services market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region occupies a significant position in the global bioanalytical testing services market. The European bioanalytical testing services market is expected to witness significant growth during the forecast period due to the strong manufacturing capabilities in the pharmaceutical, biopharmaceutical, and biotechnological industries, and the presence of leading bioanalytical testing service providers in different European countries.

Europe Bioanalytical Testing Services Market Revenue and Forecast to 2030 (US$ Million)

Europe Bioanalytical Testing Services Market Segmentation

The Europe bioanalytical testing services market is segmented based on test type, disease indication, end user, and country.

Based on test type, the Europe bioanalytical testing services market is segmented into pharmacokinetics, biomarkers, immunogenicity, virology testing, cell-based assays, and others. The cell-based assays segment held the largest market share in 2022.

Based on disease indication, the Europe bioanalytical testing services market is segmented into cardiovascular, neurological disorders, metabolic disorders, respiratory diseases, autoimmune disorder, oncology, sexual health, bone disease, and others. The oncology segment held the largest market share in 2022.

Based on end user, the Europe bioanalytical testing services market is segmented into pharmaceutical and biopharmaceutical companies, contract research organization (CRO), contract development and manufacturing organization (CDMO), and others. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2022.

Based on country, the Europe bioanalytical testing services market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe bioanalytical testing services market share in 2022.

SGS SA, Pharmaron Beijing Co Ltd, Element Materials Technology Group Ltd, Charles River Laboratories International Inc, Eurofins Scientific SE, Labcorp Drug Development Inc, Syneos Health Inc, KCAS Bioanalytical and Biomarker Services LLC, ICON Plc, and Intertek Group Plc are some of the leading companies operating in the Europe bioanalytical testing services market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe bioanalytical testing services market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe bioanalytical testing services market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe bioanalytical testing services market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution